十二/十四烷基甜菜碱 | 66455-29-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 十二/十四烷基甜菜碱
• 中文别名: 十二/十四烷基二甲基甜菜碱；去垢剂；十二-十四烷基二甲基甜菜碱
• 英文名称: Carboxymethyl-dodecyl-dimethylazanium
• CAS: 66455-29-6
• 化学式: C16H34NO2+
• 分子量: 272.45
• InChiKey: DVEKCXOJTLDBFE-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  19
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• BORON-CONTAINING SMALL MOLECULES
  申请人：Xia Yi

  公开号：US20100256092A1

  公开（公告）日：2010-10-07

  This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections.

  这项发明涉及6-取代苯硼酯化合物等物品，以及它们用于治疗细菌感染的用途。
• Boron-Containing Small Molecules as Anti-Inflammatory Agents
  申请人：ANACOR PHARMACEUTICALS, INC.

  公开号：US20150291629A1

  公开（公告）日：2015-10-15

  Compounds and methods of treating anti-inflammatory conditions are disclosed.

  化合物和治疗抗炎症状况的方法被披露。
• [EN] AMINO- OR AMMONIUM-CONTAINING SULFONIC ACID, PHOSPHONIC ACID AND CARBOXYLIC ACID DERIVATIVES AND THEIR MEDICAL USE<br/>[FR] DÉRIVÉS D'ACIDE SULFONIQUE, D'ACIDE PHOSPHONIQUE ET D'ACIDE CARBONIQUE CONTENANT UN GROUPE AMINO OU AMMONIUM ET LEUR UTILISATION MÉDICALE
  申请人：JADO TECHNOLOGIES GMBH

  公开号：WO2012160187A1

  公开（公告）日：2012-11-29

  The present invention relates to amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives, in particular the compounds of formula 1, 2, 3, 4, 5 or 6, and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder.

  本发明涉及氨基或铵基含有磺酸、膦酸和羧酸衍生物，特别是式1、2、3、4、5或6的化合物，以及它们在医学上的用途，包括它们在治疗、预防或改善炎症、自身免疫和/或过敏性疾病中的用途。
• Anionic or cationic dendrimer antimicrobial or antiparasitic compositions
  申请人：STARPHARMA LIMITED

  公开号：US20030129158A1

  公开（公告）日：2003-07-10

  To inhibit, prophylactically or therapeutically, a bacterial, yeast, fungal, or parasitic agent in a patient, an effective amount of a dendrimer is administered to the patient, which dendrimer has a plurality of terminal groups, at least one of which has an anionic- or cationic-moiety covalently bonded or linked thereto. The anionic-containing moiety is not a disaccharide or oligosaccharide moiety, and, where the anionic-containing moiety is a neuraminic- or sialic acid-containing moiety, it is modified in the 4-position by substitution with an amino, amido, cyano, azido or guanido group, or is unsaturated.

  为了抑制、预防或治疗患者体内的细菌、酵母菌、真菌或寄生虫，需要向患者注射有效量的树状分子，该树状分子具有多个末端基团，其中至少一个基团与其共价键合或连接成阳离子或阴离子基团。阴离子含有的基团不是二糖或寡糖基团，当阴离子含有的基团是神经酰胺酸或唾液酸含有的基团时，在4位被氨基、酰胺、氰基、叠氮基或鸟氨酸基团取代或不饱和。
• [EN] PHARMACEUTICAL FORMULATIONS<br/>[FR] FORMULATIONS PHARMACEUTIQUES
  申请人：MOLECULAR DEFENSES CORP

  公开号：WO2017091737A1

  公开（公告）日：2017-06-01

  Disclosed herein is glutathione in conjunction with an isoselenazol or isothiazol derivative, e.g., ebselen or ebsulfur derivative, to treat diabetes, lupus, or other chronic inflammatory disease. The glutathione is preferably provided in a rapid release oral formulation that presents the glutathione for absorption in the first part of the ileum. The isoselenazol or isothiazol derivative is preferably provided in a delayed release formulation to avoid overlapping high enteric concentration. These may be provided within the same unit dosage form.

  本文披露了谷胱甘肽与异硒唑或异硫唑衍生物（例如ebselen或ebsulfur衍生物）结合治疗糖尿病、狼疮或其他慢性炎症性疾病的方法。谷胱甘肽最好以快速释放口服制剂的形式提供，以便在回肠的第一部分中吸收谷胱甘肽。异硒唑或异硫唑衍生物最好以延迟释放制剂的形式提供，以避免重叠的高肠内浓度。这些可以在同一单位剂量形式中提供。